Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations.
Mio KanbeNoriaki SunagaKenichiro HaraHiiru SawadaIkuo WakamatsuKentaro HaraSohei MutoYuri SawadaHiroaki MasubuchiMari SatoYosuke MiuraHiroaki TsurumakiMasakiyo YatomiReiko SakuraiYasuhiko KogaYoichi OhtakiToshiteru NagashimaNaoko OkanoNobuteru KuboToshitaka MaenoTakeshi HisadaPublished in: Thoracic cancer (2022)
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are standard therapeutic agents for non-small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long-term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations. The patient received gefitinib monotherapy, systemic chemotherapy/chemoimmunotherapy, and local consolidative therapies for oligometastatic lesions, and responded to afatinib rechallenge with a progression-free survival of 12 months. The current case suggests that afatinib is effective in NSCLC patients with EGFR L858R and L747V mutations and that a therapeutic approach combining appropriately timed systemic therapies with local consolidative therapies for oligometastatic lesions improves long-term survival.